United States Patent 7,182,961 Landscape: Scope and Claim-Chart Read Across Pulmonary Inhalation Particles with Collapsed Hollow-Sphere Microparticles

US 7,182,961 is directed to inhalable particulate compositions defined by a combination of (i) low tap density, (ii) aerodynamic-relevant median/geometry size in the > about 5 μm range, (iii) high external surface area, and (iv) a “continuous collapsed hollow sphere wall” with a thin-wall constraint (≤ about 150 nm) and optionally strong fine-particle fraction. Dependent claims add tight ranges for dispersibility ratio (1.0 to 1.5 by RODOS/HELOS laser diffraction), “surface area factor” thresholds (>2, >3), higher external surface area cutoffs (≥8 and ≥10 m2/g), and even lower tap density (<0.1 g/cm3). The independent claim set culminates in formulations for drug delivery (composition claims) and methods for administering by inhalation (method claims). The practical IP risk zone is not generic “inhalation particles” broadly, but rather particle engineering that reproduces the structural wall morphology (collapsed hollow sphere with continuous wall and thin wall) paired with the specific physical property targets used by the patent.

What does US 7,182,961 claim cover: collapsed hollow-sphere inhalable particles with low tap density and high surface area?

Core claim theme: The patent defines a pulmonary delivery particulate by a structural particle architecture (continuous collapsed hollow sphere wall) plus quantitative bulk and surface properties (tap density, particle size, external surface area, skeletal density in one branch, and fine-particle fraction in another branch). It also allows incorporation of a drug and excipient, and includes administration by inhalation.

Independent claims: what exact particle attributes are required

From the claim text provided, the independent compositions are built around three main “particle spec packages”:

Package A (claims 1 and 4): size and surface area with collapsed hollow sphere wall

Tap density: < 0.4 g/cm3
Median geometric diameter: > about 5 μm
External surface area: > about 5 m2/g
Morphology: continuous collapsed hollow sphere wall
Optional dispersibility ratio: 1.0 to 1.5 (RODOS/HELOS laser diffraction) (claim 4)

This package targets engineered inhalable porous/low-density powders with high accessible surface and controlled dispersibility.

Package B (claims 10, 16, 20, 28): adds skeletal density and thin-wall constraint

Tap density: < 0.4 g/cm3 (claims 10, 20, 28) or <0.1 g/cm3 (claims 9, 19, 26, 28)
Geometric diameter: > about 5 μm
External surface area: ≥ about 5 m2/g (claim 20) or ≥ about 8 m2/g (claim 28) or > about 10 m2/g (claim 18, 25)
Morphology: continuous collapsed hollow sphere wall
Thin wall: wall thickness < about 150 nm (claim 20)
Skeletal density: ≥ about 1 g/cm3 (claim 10 branch)

Claim 20 and claim 28 are the tightest structural-property couplers because they expressly require wall thickness <150 nm in the presence of the hollow collapsed wall.

Package C (claim 20/28): adds fine particle fraction

At least 70% of particles have fine particle fraction of < about 5.6 μm (claim 21)
Continued requirements from claim 20 or claim 28, including collapsed hollow sphere wall and thin wall <150 nm

This is an inhalation-performance constraint. It attempts to ensure the engineered powder is not only low density/high surface, but also capable of producing respirable-size fractions under test/characterization conditions.

Methods claims: inhalation

Claim 27: administering by inhaling the composition of claim 20
Claim 29: administering by inhaling the composition of claim 28

These are “use” claims tethered to the structural and physical powder specs. Practically, they extend enforcement to dosing regimens/products so long as the administered powder matches the claim limitations.

How broad are the claims: where are the infringement “hooks” and where do they narrow?

Breadth drivers

“Continuous collapsed hollow sphere wall” is a broad morphology descriptor relative to fully specified pore sizes, chemistries, or drug identities. It covers a category of particle wall collapse structures.
The composition claims are not limited to a specific drug molecule in your excerpt (claims 2, 3, 11, 12 state “drug” and “pharmaceutical excipient” generally).
Particle size is anchored by a lower bound only (> about 5 μm). That is broader than claims with an upper size limit, though other constraints (fine particle fraction) effectively cap the relevant distribution.

Narrowing and quantification that materially reduce scope

Tap density thresholds: <0.4 g/cm3 and in multiple dependent claims <0.1 g/cm3. Low tap density is measurable and constraining.
External surface area cutoffs: >5 m2/g (base), >8 m2/g, >10 m2/g. This drives a particular porous morphology/processing regime.
Wall thickness <150 nm (claim 20; also reflected in claim 28). This is a high-bar structural specification. If the wall is thicker, non-infringement follows even if tap density and surface area are in range.
Fine particle fraction constraint: ≥70% with fine particle fraction <5.6 μm (claim 21). This ties the distribution tail to inhalation performance.

Measurement-defined constraints create a de facto “procedural” boundary

The dispersibility ratio range (claim 4) specifies the RODOS/HELOS system. That makes infringement sensitive to the test method and how the accused product is characterized. Even if a competitor achieves similar engineering, failure to meet the same measurement framework can matter in claim construction and evidence.

What is the legal structure of the claim set: composition vs method, and where dependent claims expand coverage?

Composition claims

Claims 1 to 26 establish inhalable particulate compositions meeting a layered parameter set.
Claims 2-3 and 11-12 allow broad inclusion of a drug and excipient.
Claims 4, 5-8, 9 and the analogs in the claim 10 branch provide incremental “claim ladder” coverage.

Method claims

Claims 27 and 29 are narrow because they require inhalation of compositions that satisfy the composition claim specifications (claim 20 and claim 28, respectively).

Practical interpretation: “thin-wall” and “fine fraction” are the key differentiators

In infringement analysis, the most decisive elements are:

continuous collapsed hollow sphere wall
wall thickness <150 nm
external surface area minimums
tap density
fine particle fraction (for claims incorporating claim 21 style limitations)

What particle characteristics are explicitly required: tap density, size distribution, surface area, dispersibility ratio, and skeletal density?

Claim parameter table (from your provided text)

Parameter	Threshold(s) appearing in claims	Where it matters
Tap density	<0.4 g/cm3	Claims 1, 10, 20, 28; and indirectly others (via dependencies)
Tap density (more stringent)	<0.1 g/cm3	Claims 9, 19, 26; claim 28 includes <0.1
Median geometric diameter	>~5 μm	Claim 1; also claim 20 and 28 via “geometric diameter/diameter” terms
External surface area	>~5 m2/g	Claim 1; claim 20 has “at least” ~5 m2/g
External surface area (higher)	>~8 m2/g	Claims 7, 17, 24, 28 requires ≥~8
External surface area (highest)	>~10 m2/g	Claims 8, 18, 25
Wall morphology	continuous collapsed hollow sphere wall	Claim 1; repeated across claim 10, 16, 20, 28
Wall thickness	<~150 nm	Claim 20 and claim 28
Skeletal density	≥~1 g/cm3	Claim 10
Dispersibility ratio	~1.0 to ~1.5 (RODOS/HELOS)	Claim 4 and claim 13
Surface area factor	>2	Claims 5, 14, 22
Surface area factor	>3	Claims 6, 15, 23
Fine particle fraction	≥70% with fine fraction <~5.6 μm	Claim 21
Inhalation method	inhaling composition	Claims 27 and 29

What formulations are protected: drugs plus excipients combined with the specified particle engineering?

Your excerpt shows the patent covers:

Drug-containing compositions: claim 2, 3, 11, 12
Any pharmaceutical excipient (at least as far as claim language goes): claims 3 and 12

That means the primary limitation is the particle rather than a specific drug substance. Once a competitor uses a drug (including the same drug as in a licensed product) in a powder that meets the claimed engineered particle profile, formulation-level changes may not avoid infringement.

In enforcement terms, the “escape valves” are usually:

changing particle morphology so the wall is not “continuous collapsed hollow sphere wall,” or
increasing wall thickness above 150 nm,
changing external surface area below the asserted threshold,
changing tap density beyond the thresholds,
altering fine particle fraction so that ≥70% is not achieved under the tested characterization.

What patent scope likely does not cover: beyond inhalation powders, and particle types without the collapsed hollow sphere wall

Based on the claim text alone, US 7,182,961 does not read naturally onto:

non-hollow porous particles without the “collapsed hollow sphere” architecture,
solid particles with comparable surface area but not a continuous collapsed hollow sphere wall,
formulations where wall thickness is not <150 nm when claims 20/28 are asserted,
inhalation products that use large agglomerates where the fine particle fraction requirement is not met.

These are practical “claim map” boundaries because each is explicitly limited in your supplied claims.

How strong is the patent estate for US 7,182,961: what does this imply about validity and enforceability leverage?

The provided claims are heavy on measurable physical parameters, which tends to:

strengthen enforceability via objective test metrics, and
increase invalidity risk if prior art discloses the same parameter combinations.

However, without the specification text, prosecution history, and the cited art list tied to US 7,182,961, a rigorous strength assessment and a full “scope vs prior art” validity analysis cannot be completed from claim language alone.

How does this compare with typical pulmonary powder IP: does it look like spray-dried, co-milled, or engineered porous hollow particles?

The claim phrase “continuous collapsed hollow sphere wall” and thin wall <150 nm align most closely with engineered hollow-shell or spray-formed hollow microparticles that collapse during formation or processing, rather than conventional micronized solids.

From a competitive standpoint, the closest design-around patterns generally target:

shell collapse mechanism so the wall is not “continuous collapsed,”
retaining thicker walls,
lowering external surface area to below the minimum thresholds,
changing size distributions to fail fine particle fraction.

This kind of particle IP typically forces competitors into either a different particle morphology platform or a materially different powder performance target.

What generic entry risks exist for inhaled drugs covered by this patent?

The risk is not driven by drug identity but by powder platform. Generic entry risk arises when:

a generic applicant copies the same inhaled product formulation technology (particle morphology and performance spec), and
the generic’s powder falls within the claimed physical property bounds.

If the generic applicant uses a different particle engineering platform that fails the “collapsed hollow sphere wall” or the thin-wall constraint, the generic’s legal risk drops even if the delivered drug dose and clinical effect are the same.

What patent litigation affects US 7,182,961 specifically?

No litigation history can be stated from the information provided in your prompt. Without the litigation docket references, filings, and court outcomes, a reliable “who is challenging whom” landscape cannot be produced.

Orange Book status and FDA regulatory posture of the relevant products

This requires the associated drug product(s) and Orange Book listing(s) tied to US 7,182,961. The provided prompt includes only claim text and not the associated NDA/ANDA/BLA, proprietary name(s), or the FDA listing. Without those, an accurate Orange Book status mapping cannot be generated.

Key Takeaways

US 7,182,961 protects inhalable pulmonary particulate compositions defined by a specific engineered particle architecture: continuous collapsed hollow sphere wall.
The strongest infringement constraints are the quantified physical specs: low tap density (<0.4; and in tighter dependent claims <0.1), high external surface area (>5, >8, >10 m2/g), and for the tightest claims wall thickness <150 nm plus (in one branch) ≥70% fine particle fraction <5.6 μm.
Drug and excipient are broadly permitted in the claim framework; the practical design-around path is therefore usually particle-morphology and powder-property change, not simply switching excipients or the drug.
Method claims extend the composition to inhalation administration but remain tethered to the same particulate limitations (claims 20/28).

FAQs

1) What element is most likely required to prove infringement of US 7,182,961?
The combination of continuous collapsed hollow sphere wall and the accompanying quantitative powder property thresholds (especially external surface area and, for tighter claims, wall thickness <150 nm).

2) Can changing the drug avoid infringement if the particle still matches the claimed physical specs?
Under the claim text provided, swapping the drug does not avoid infringement if the composition still meets the particle-defined limitations (claims 2/3 and 11/12 keep drug/ excipient flexible).

3) How do the tap density and external surface area limits function in a legal claim map?
They are objective, testable constraints; failure to meet the thresholds is a direct route to non-infringement for the asserted claim.

4) What do the RODOS/HELOS dispersibility ratio range claims add strategically?
They narrow the scope to powders that meet a specified dispersibility performance measured on that system (claims 4 and 13).

5) What’s the highest-risk design target for competitors trying to work around this patent?
Replicating the platform that satisfies collapsed hollow sphere morphology while also achieving wall thickness <150 nm, high external surface area, and (where required) ≥70% fine particle fraction <5.6 μm.

References

United States Patent 7,182,961 (claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002352836	⤷ Start Trial
Canada	2465675	⤷ Start Trial
Denmark	1455755	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,182,961

Summary for Patent: 7,182,961